• Strengthens its support to an “Atmanirbhar India” by promoting indigenous technology on a global scale with 52 patents in India and the U.S

India, May,2020

Healthium Medtech, one of the largest medical device companies in India, today announced the launch ofthe first of its kind Anti-Microbial Gloves, TruShield. Manufactured atKunigal, Karnataka, these Anti-Microbial Gloves (AMGs)aremade from a patented technology using a Quaternary Ammonium Compound that kills microbes and provides 99.99% protection forHealthcare professionals(HCPs)andpatients upto 8 hours.

The Anti-Microbial gloves are the 3rdInnovative launch for Healthium in the last 6 months. The company had launched Truglyde SN2355, a suture needles combination specially created for COMOC MG, an Innovative surgical technique to manage Postpartum Hemorrhage (PPH), which is one of the largest causes for maternal mortality. Healthium also launched the largest shoulder range of Arthroscopic devices in India benefitting Arthroscopy surgeons through simplified and functional patented designs. The Company holds 52 patents in India and the U.S.

Speaking on the occasion,Anish Bafna, Group Chief Executive Officer & Managing Director, Healthium said, “We constantly endeavor to simplify for the medical fraternity through innovative precision based medical devices manufactured indigenously across our 5 facilities in India. 85%of medical devices in India areimported . As an Indian player delivering to global standards with US FDA(510k), CE and ISO approvals and 52 patents in India and U.S, we are working relentlessly to reduce the dependence on imported technology and support a self-reliant(Atmanirbhar) India. With the launch ofTrushieldAMG, we would like to further protect the hands that save lives”

The surgical gloves available today, do not provide complete protection as they merely act as a passive barrier1.Doctors are at particular risk2 because their work demands close contact with patients who may be harboring pathogenic microbes.

Breaching of gloves during surgery when unnoticed by the operating surgeons brings an occult risk3 to the surgeon as well as the patients.Even the efficacy of scrubbing before surgery begins to fade in 3 hours and post 54 hours into surgery, contamination reaches pre-scrub levels. This makes both surgeons and patients vulnerable.

Speaking at the Launch, Dr Ashok Moharana, Chief Medical Officer at Healthium Medtech said, “Studies have shown that Surgical Site Infections account for 15% of all Healthcare Associated Infection (HAI) and 37%5 of HAI in surgical patients, putting patients at risk. On the other hand, over 45% Surgeons’ gloves get breached mostly on non-dominant hands and only 25%3notice the puncture during surgery, bringing an occult risk for HCPs. Enhancing protection from contact transmissionfor an extended duration is an unmet need today and to address this, we have launched TRUSHIELD Anti-microbial gloves. With a novel mechanism of action, this is an effective solution that protects both HCPs and patients against a range of microbes. TRISHIELD AMG is non-leaching and offers 99.99% microbicidal protectionlasting upto 8 hrs.”

Ehsan Huq, SVP - Commercial, Healthium Medtech said, “Collaboration is a core value at Healthium; launching TRUSHIELD AMG during the lockdown validates our commitment to partner with surgeons and their patients in successful outcomes. Improving access is our vision; TRUSHIELD AMG is supported by the Healthium team and available through our extensive distribution footprint, covering in excess of 500 towns and cities in India.”

Sources

  • Patient safety and quality: An evidence based hand book for nurses, Vol-2, Pg. 2-557
  • Sepkowitz KA, Eisenberg L: Occupational deaths among healthcare workers. Emerg Infect Dis 2005, 11(7):1003–1008.
  • Prasad HP et al. Surgical Glove Perforation: An Indiscernible Hazard. Indian Journal of Contemporary Surgery, 5(2):144-177
  • Hosseini, P., Mundis, G.M., Eastlack, R. et al. Do Longer Surgical Procedures Result in Greater Contamination of Surgeons’ Hands?.ClinOrthopRelat Res 474, 1707–1713 (2016).
  • Prevention of Hospital Acquired Infections: A practical Guide 2nd edition. Editors G Ducel, J Gabry and L Nicolle. Published by World Health Organisation 2002.

About Healthium Medtech:
The Healthium Group is a conglomerate consisting of Healthium MedtechPvt. Ltd., one of the largest players in the Indian Medical Devices Market, QNPL, the largest independent manufacturer of Surgical suture needles worldwide by volume, and Clinisupplies a leading player in Urology Consumables in the United Kingdom.

The Healthium Group has a lineage of 36 years in creating precision based medical devices across the world. Its products are used in 1 in 6 surgeries globally.

With a Vision to create access to Precision Medtech for every patient globally, Healthium Medtech is present in over 70 countries, covers 18000+ hospitals across India and has a workforce of 1500 employees of which 60% are women. Its portfolio includes Minimally Invasive Arthroscopy implants and Endoscopy staplers and cutters, a full range of Absorbable, Non-Absorbable and Specialty Surgical Sutures, Wound Closure products including Hernia Meshes, Skin Staplers, Cardiac Pacing Wires and Haemostats.

Healthium has 6 Manufacturing facilities across India and the UAE and the Company holds over 52 patents in India and the U.S, including those applied for. Backed by stringent R & D norms, the Company’s products adhere to the highest globalquality standards, having accreditations and approvals from 510k (USFDA), CE & ISO.

HEALTHIUM MEDTECH LTD

(formerly known as Healthium Medtech Private Limited)

472/D, 13th Cross, 4th Phase, Peenya Industrial Area, Peenya Industrial Area Phase IV, Peenya, Bengaluru, Karnataka - 560 058, INDIA

CIN: U03311KA1992PLC013831

contact@healthiummedtech.com

For any queries or complaints write to
care@healthiummedtech.com

Customer care number
+91-80-41868000

DISCLAIMER

“Healthium Medtech Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus (“DRHP”) with the Securities and Exchange Board of India. The DRHP is available on the website of the SEBI at www.sebi.gov.in as well as on the websites of the book running lead managers, ICICI Securities Limited, CLSA India Private Limited, Credit Suisse Securities (India) Private Limited and Nomura Financial Advisory and Securities (India) Private Limited, at www.icicisecurities.com, www.india.clsa.com, www.credit-suisse.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively, and the websites of the stock exchange(s) at www.bseindia.com and www.nseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" of the RHP / Prospectus, when available. Potential investors should not rely on the DRHP for any investment decision.”

We use cookies to ensure you get the best experience on our website. Click here to view cookie policy